Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have been given an average rating of “Buy” by the thirteen analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $39.80.

Several equities analysts have recently issued reports on CNTA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Oppenheimer boosted their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Truist Financial upped their price objective on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd.

Insider Buying and Selling

In other news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 349,073 shares of company stock valued at $9,429,412 over the last three months. Corporate insiders own 7.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in CNTA. Virtus Investment Advisers LLC lifted its position in Centessa Pharmaceuticals by 6.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock valued at $251,000 after buying an additional 583 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after buying an additional 870 shares during the period. Coastal Bridge Advisors LLC increased its stake in shares of Centessa Pharmaceuticals by 7.1% in the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after acquiring an additional 931 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after acquiring an additional 979 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $25,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $28.70 on Monday. The stock’s 50-day moving average is $25.85 and its 200 day moving average is $25.08. The company has a market cap of $4.19 billion, a PE ratio of -15.68 and a beta of 1.54. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.